Abstract:At present, cancer nanomedicine mainly focuses on mitigating adverse effects but fails to enhance the therapeutic efficacies of anticancer drugs. With the benchmark of the recent highly effective molecular targeted therapies and immunotherapies, rational design of next-generation cancer nanomedicine should aim at enhancing its therapeutic efficacy. From this point of view, this review first analyszs the typical cancer-drug-delivery process of an intravenously administered nanomedicine and concludes as a cascade of five steps, including circulation in the blood compartments, accumulation in the tumor, subsequent penetration deep into the tumor tissue to reach tumor cells, internalization into those cells, and finally intracellular drug release (CAPIR cascade for short). High efficiency of every step is critical for a nanomedicine to achieve a high overall delivery efficiency and thereby improve the whole therapeutic efficiency. Further analysis shows that to maximize its efficiency, the nanoproperties required in each step for a nanomedicine are different and even opposite in different steps, such as PEG, surface-charge, size, and stability dilemmas To resolve these dilemmas and integrate all the required nanoproperties into one nanomedicine, stability, surface, and size nanoproperty transitions (3S transitions for short) are proposed. Stimulus-responsive polymers have been designed to realize the 3S transitions, including pH-, ROS-, redox-, enzyme-responsive, and so on. Smart nanomedicines possessing the 3S transitions are demonstrated. The challenges in designing high-performance cancer nanomedicines and their clinical translations are then discussed. Clinical translation is the ultimate goal of nanomedicine research. To design translational nanomedicines, the three key elements, 3S transition capability, material excipientability, and process scale-up ability (CES elements for short) must be considered. Our recent development of noncytotoxic with highly potent therapeutic polymers as a new type of molecular nanomedicine is summarized Finally, by comparing viral vectors, a possible solution for multifunctional nanomedicines to realize their clinical translation is proposed.

Nanomedicines with Versatile GSH-Responsive Linkers for Cancer Theranostics

Glutathione-mediated nanomedicines for cancer diagnosis and therapy

Glutathione-responsive and -exhausting metal nanomedicines for robust synergistic cancer therapy

Responsive nanoplatforms: Versatile design strategies for efficient cancer theranostics

Engineering Thio-/seleno-ether Linkers into Zwitterionic Small Molecule Nano-prodrugs for Traceable Cancer Theranostics

Redox-manipulating nanocarriers for anticancer drug delivery: a systematic review

Applications of Gold Nanoparticles in Cancer Nanotechnology.

Glutathione-Responsive Multifunctional “Trojan Horse” Nanogel as a Nanotheranostic for Combined Chemotherapy and Photodynamic Anticancer Therapy

Biomimic Binding Affinity Gradients Triggered GSH‐Response of Core–Shell Nanoparticles for Cascade Chemo/Chemodynamic Therapy

Gold Nanoparticles in Cancer Theranostics

Nanoparticle-based medicines in clinical cancer therapy

Redox‐Responsive Self‐Assembled Nanoparticles for Cancer Therapy

Functional gadolinium-based nanoscale systems for cancer theranostics

Recent advances in dual- and multi-responsive nanomedicines for precision cancer therapy

Stimuli Responsive Nanoparticles for Controlled Anti-cancer Drug Release

Gold-Nanoparticle Hybrid Nanostructures for Multimodal Cancer Therapy

Polymeric Cancer Nanomedicines: Challenge and Development

Gsh-Responsive Nanoprodrug To Inhibit Glycolysis And Alleviate Immunosuppression For Cancer Therapy

Polymer-Based Cancer Nanotheranostics: Retrospectives of Multi-Functionalities and Pharmacokinetics

Stimuli-Responsive Nanomaterials for Application in Antitumor Therapy and Drug Delivery

Mesoporous silica nanotechnology: promising advances in augmenting cancer theranostics